Uncommon EGFR Mutations Research Overview
At MOASC Spotlight 2025, Dr. Darren Wijaya, MD, from Loma Linda University Health, shared vital research. It focused on rare and uncommon EGFR mutations in metastatic lung cancer. Uncommon EGFR mutations in lung cancer present unique challenges in treatment. The study involved 10 patients. Dr. Wijaya is a third-year internal medicine resident. Learn more about his work here.
Key Results for Rare EGFR Changes
The study showed a Median Progression-Free Survival (PFS) of 15.81 months. Furthermore, the Median Duration of Response (DoR) was 22.1 months. Additionally, the Objective Response Rate (ORR) hit 40% at 6 months. This was with osimertinib as first-line therapy for those with uncommon EGFR mutations lung cancer. Intracranial PFS was 14.73 months. The ORR for brain response was 40% at 6 months.
Study Methods on Lung Cancer Variants
Five patients had single rare mutations. The other five had compound changes. The research used a retrospective cohort approach to study uncommon EGFR mutations lung cancer. It evaluated EGFR TKIs like osimertinib. Disease control rate (DCR) was 100% at 6 months. However, it dropped to 70% at 12 months.
Future Directions for EGFR Mutation Studies
Dr. Wijaya suggests more studies. He recommends meta-analyses or prospective trials. The project is in manuscript submission now. This could enhance lung cancer treatments. Stay tuned for updates.
Lung Cancer Context with Rare Mutations
Rare EGFR changes differ from common types. Osimertinib is key for brain metastases. It showed strong efficacy. Half the patients had intracranial issues due to uncommon EGFR mutations lung cancer. This highlights treatment potential.
[Image: Chart of PFS and ORR data] Alt text: Chart showing rare EGFR mutation lung cancer treatment results
Final Thoughts on Mutation Treatments
This research offers hope. It targets complex mutation profiles. Future trials could validate results for. Dr. Wijaya’s work may shape oncology care.
https://oncologytube.com/lung-cancer-asco-2025-updates-dr-villalona-calero/